Introduction
A common definition of hemostasis is the process that arrests bleeding, or, in other words, the biological mechanisms that keep blood within a damaged blood vessel. The processes involved have been described in detail elsewhere [1] , and include platelet adhesion, activation, and aggregation, as well as coagulation activation and propagation. The final product of hemostasis is the formation of a platelet plug stabilized by crosslinked fibrin fibers. According to the definition of hemostasis, pleiotropic effects of hemostasis are the actions of components or key players of this mechanism beyond the activity of platelets and the formation of fibrin. For the structure of this article, we followed this reasoning, and sectioned the text into actions of platelets and coagulation proteases not causing a platelet/fibrin clot, with a focus on cardiovascular disease and atherosclerosis.
Platelets
The role of platelets in cardiovascular disease, and more specifically in atherosclerosis, is diverse. Although atherosclerosis is a long-term process, platelets are known to exert effects throughout all stages of the inflammatory disease. Platelets contribute to early atherosclerosis by adhering to the activated endothelial monolayer, in a process mediated by platelet P-selectin [2] . By adhering to the endothelium, platelets are activated, leading to the release of proinflammatory cytokines such as interleukin (IL)-1b [3] . The interaction between endothelial cells and platelets also induces the expression of adhesion molecules, and thereby promotes leukocyte adhesion and monocyte recruitment [4, 5] . After an activated platelet transmigrates into the plaque, it secretes even more IL-1b, among other proinflammatory cytokines. Furthermore, and perhaps even more importantly, platelets interact with dendritic cells, which are classical antigen-presenting cells. This interaction initiates and promotes lesion growth via recruitment of lipids into atherosclerotic plaques [6] . In the late stages of atherosclerosis, platelets are well known to play a key role in thrombus formation on eroded plaques or after plaque rupture [7] .
of the 20th century that the so-called PARs were discovered. To date, a total of four PARs (PAR1, PAR2, PAR3, and PAR4) have been identified, and their expression has been demonstrated on platelets, vascular smooth muscle cells, endothelial cells, and leukocytes, among other cell types. The PARs belong to the family of G-protein-coupled receptors, and activation of the receptor takes place by proteolysis of the N-terminal domain, generating a new so-called tethered ligand to be exposed to the receptor.
The presence of PARs on platelets has been demonstrated by Vu et al. [8] , and so far only PAR1 and PAR4 have been identified on human platelets [9] . In contrast, mouse platelets express PAR3 and PAR4 [10, 11] . For human platelets, PAR1 plays a key role in activation, requiring only very low thrombin concentrations, whereas PAR4 needs high concentrations of thrombin to have an effect on platelets [12] . Upon activation of PAR1, heterotrimeric G-proteins have, through intracellular signaling, several effects, including thromboxane A 2 production, ADP release, activation of P-selectin, and platelet aggregation. The hemostatic effect of PAR activation on platelets is further facilitated by the formation of a procoagulant phospholipid membrane through stimulation of phosphatidyl serine exposure [13] [14] [15] . The role of PAR4 in platelets is less evident; however, it is thought that PAR4 acts as a support mechanism for thrombinmediated PAR1 signaling.
Activators of PARs can be divided into coagulation proteases and non-coagulation proteases. All four PARs can be activated by one or more coagulation proteases. PAR1, PAR3 and PAR4 are activated by thrombin, whereas PAR2 is activated by activated factor X (FXa) and activated factor VII (FVIIa) [1, 16] . Recent studies, however, have also shown activation of PAR2 by high concentrations of thrombin, and activation of PAR1 and PAR3 by FXa [17] [18] [19] . PAR1 can also be activated by the anticoagulant activated protein C (APC) at a site downstream of thrombin activation, resulting in a different amino acid composition of the N-terminal-tethered ligand [20, 21] . Other proteases that can activate PAR1 include neutrophil-derived cathepsin G [22] , neutrophil elastase [23] , and several metalloproteinases such as ADAM-17 [24, 25] , matrix metalloproteinase (MMP)-1, MMP-9, and MMP-13. Cathepsin S, chitinase and MT-SP1/matriptase have been identified as agonists of PAR2 [26] .
Regarding PAR4 activation, cathepsin G, kallikrein 1 and plasmin are known for their proatherogenic properties, inducing cell-specific events such as proliferation and adhesion [27, 28] .
In addition to undergoing monomeric activation, PARs can form homodimers, heterodimers, and even oligomers, thereby diversifying their effects on biology and pathology. After the formation of a PAR1-PAR2 complex, barrestin-mediated extracellular signal-regulated kinase (ERK) 1/2 signaling is greatly enhanced. It is tempting to speculate that PAR1-PAR2 complex formation is proatherogenic, given the fact that ERK1/2 activation is highly proatherogenic [29, 30] .
Activation of PARs induces site-specific effects, and the effects may differ between receptors. Functions of PAR activation become visible early on, when PAR1 is required for normal vascular development in the embryo. PARs also play an important role in vascular tone regulation, with PAR1 and PAR2 being able to induce vasorelaxation through an endothelial-dependent mechanism. During vascular injury, PAR1 increases endothelial permeability and the extravasation of proteins. Furthermore, PAR1 recruits platelets and leukocytes to injured surfaces via increased expression of cytokines and adhesion molecules. Vascular remodeling is promoted by PARs via stimulation of endothelial and smooth muscle cell proliferation [31] .
Mechanisms of PAR activation in atherosclerosis and atherothrombosis
Early studies investigating mouse vascular tissue demonstrated that PARs might play a pathophysiological role in the development of experimental atherosclerosis (Fig. 1 ) [32, 33] . In these early years, many effects of PARs were identified, including modulation of the vascular tone by a nitric oxide mechanism [34] , induction of vascular smooth muscle cell growth [35] , and inflammatory-driven atherogenesis [36] .
Evidence for a role of PARs in the development and progression of atherosclerosis stems from experiments with several animal models with deficiencies of the receptors on an atherogenic background. Deficiency of PAR2 has been shown to attenuate atherosclerosis [37] , whereas, in contrast, PAR4 deficiency on an ApoE À/À background did not alter the extent of atherosclerosis as compared with wild-type animals [38] . Although the exact mechanisms of PARs in atherosclerosis have yet to be established, several potential pathways have been studied. In the early stages of atherosclerosis, proliferation and migration of smooth muscle cells takes place, together with apoptosis of endothelial cells. The proliferation of smooth muscle cells is partially induced by PAR2 activation, facilitated by factors such as tumor necrosis factor (TNF)-a and IL-1b. Activation of PAR2 can take place on macrophages and vascular smooth muscle cells, among other cells, in atherosclerotic plaques. Consequently, a complex of MT-SP1/matriptase stimulates the synthesis of the proinflammatory cytokines IL-8 and IL-6, enhancing inflammatory processes in the endothelial layer of the arterial vessel wall and thereby inducing progression of atherosclerosis ( Fig. 2) . MT-SP1/matriptase does not seem to be a key regulator in the proinflammatory response, but can rather be seen as an amplifier of inflammation [26] . Furthermore, activation of PAR2 leads to nuclear factor-jB signaling in coronary smooth muscle cells accompanied by increased production of cyclooxygenase, both of which are associated with increased inflammation and progression of atherosclerosis [39] . PAR2 activation also directly increases adhesion of inflammatory cells to the vascular endothelium, as leukocyte adhesion is significantly decreased in PAR2 À/À mice [40] . Finally, as PAR2 can modulate the vascular tone, it is considered to be an important physiological regulator of blood pressure; upregulation of PAR2 can lower the blood pressure, whereas downregulation increases the blood pressure [41] . MMP-9-mediated PAR1 activation contributes to endothelial dysfunction, which is one of the initial stages in atherogenesis and is potentially involved in thrombosis and restenosis [42] . MMP-9 is a member of the zincdependent endopeptidase family, which can be divided into collagenases, gelatinases, stromelysins, and metalloelastases. Almost all MMPs are secreted as zymogens, and are then activated after their inhibitory domain is cleaved off. Along with MMP-9, four other metalloproteinases (MMP-1, MMP-2, MMP-13, and MMP-14) are expressed in the vascular wall. The expression of MMP-1 by macrophages, smooth muscle cells and endothelial cells is increased in atherosclerosis, and is mostly seen in vulnerable regions of atherosclerotic plaques. The role of MMP-2 and PAR1 activation remains unclear, but it has been suggested that MMP-2 is involved in monocyte migration or macrophage proliferation [43] . It has been demonstrated that atherosclerotic plaques are significantly reduced in MMP-2 À/À /ApoE À/À mice [44] . Summarizing the above-described MMP effects, it is possible that, by antagonizing MMP PAR1 activation, the processes of atherosclerosis and atherothrombosis could be counteracted. The best antagonist that could be used in such a situation would be a PAR1 antagonist [45] . However, administration of a PAR1 antagonist also counteracts several APC-mediated protective mechanisms of PAR1 activation. One of the most important mechanisms is induced by PAR1 activation on endothelial cells by APC, leading to upregulation of monocyte chemotactic protein 1 (MCP-1), which promotes both anti-inflammatory effects, through immune-modulatory chemokine networks [46] , and proinflammatory effects, by influencing the growth of different cell types [47] . It would be ideal to inhibit PAR1 activation through blockade of a specific agonist such as an MMP. Unfortunately, there is no evidence available yet regarding the selective blocking of PAR agonists, although research is progressing. The use of pepducins, which are peptides acting as intracellular inhibitors/agonists of signaling from receptor to G-protein, is currently under investigation [48] . A newly developed PAR2 pepducin antagonist, for example, caused suppression of leukocyte infiltration in vivo [49] .
Role of specific coagulation factors in atherosclerosis
Tissue factor (TF). TF is an important cytokine receptor that is a key player in the initiation of atherothrombosis and is the high-affinity receptor for FVIIa [50] . It is mostly expressed by extravascular cells [51] , but high concentrations have been identified in atherosclerotic plaques as well [52] . In plaques, TF mainly originates from macrophages, but vascular smooth muscle cells and endothelial cells are also able to express TF [53, 54] . Even though TF-FVIIa might be an important direct (PAR2) or indirect (coagulation activation) regulator of atherosclerotic progression, the main clinical effect of this protein can be seen when it initiates atherothrombosis. TF appears to be the most abundant protein in thrombogenicity during plaque rupture. The rupture itself depends on the composition of the plaque, but the size of the thrombus that is formed upon rupture is dependent on the concentration of TF present [55] . Furthermore, it has been suggested that TF plays an important role in the progression of atherosclerotic plaques by increasing macrophage apoptosis and necrosis in the lesion [52, 56] . Studies with genetically modified mice on an atherosclerotic background that express no wild-type TF but express a low level of human TF have failed to show a contribution of TF to atherogenesis [57] . However, the TF-FVIIa complex has been shown to activate PAR2 [58] , and is known to upregulate cytokines (e.g. IL-6 and IL-8) and chemokines that induce leukocyte recruitment at the site of atherosclerosis, leading to further progression of the lesion. Furthermore, TF-FVIIa-mediated PAR2 signaling increases the migration of vascular smooth muscle cells, which express receptors that are needed for lipid accumulation inside the plaque [56] .
FX. FX is expressed by macrophages and vascular smooth muscle cells in atherosclerotic lesions. The active protease, FXa, can activate both PAR1 and PAR2 on cells within the (atherosclerotic) vessel wall, including endothelial cells, leukocytes, smooth muscle cells, and macrophages. Responses mediated by FXa signaling include tissue remodeling and fibrosis, through the induction of chemokine and cytokine expression [59, 60] . Inhibition of FXa, e.g. by administration of rivaroxaban, reduces the expression of proinflammatory mediators (e.g. IL-6 and MCP-1) in ApoE À/À mice. FXa inhibition also increases the fibrotic cap thickness and reduces medial erosion, both of which lead to greater plaque stability [61] . Furthermore, following administration of an FXa inhibitor, leukocyte adhesion is attenuated in mice with metabolic syndrome [62] .
Thrombin. Thrombin can be locally generated within the atherosclerotic lesion, because FVII and FX are, along with TF, functionally expressed by both macrophages and smooth muscle cells within atherosclerotic plaques [63, 64] . In the early stages of atherosclerosis, thrombin stimulates reactive oxygen species (ROS) production, leading to apoptosis and lipid peroxidation. Furthermore, thrombin induces recruitment of monocytes into the vessel wall through synthesis of MCP-1, and increases the expression of interleukins and TNF-a. Thrombin also contributes to atherogenesis by upregulating the expression of VCAM and ICAM, both of which aid leukocyte transmigration through the endothelium [65, 66] . In a study by Borissoff et al., ApoE À/À mice with a genetically imposed 50% reduction in prothrombin expression were investigated. During atherogenesis, neutrophil mobilization was enhanced by a hypercoagulable state imposed in mice that had a point mutation in the thrombomodulin gene, creating a hypercoagulable state with diminished cytoprotective activation of APC. In these animals, there were increases in oxidative stress and apoptosis, both of which promote atherosclerotic plaque progression and eventually atherothrombosis [67] . In contrast, another study with comparable mice genotypes demonstrated that, during de novo atherogenesis, thrombin-induced signaling via PAR1 signaling impairs the migration of monocytes, resulting in a reduction in macrophage accumulation in atherosclerotic plaques, thereby having a protective effect [68] . Although a clear explanation for the contradictory data obtained with comparable genotypes is still lacking, the effects of different conditions, including the age of animals and the administered diet, cannot be excluded.
Other coagulation factors. Other coagulation factors have been studied in less detail. Studies performed with ApoE À/À mice showed an approximately 30% reduction in atherosclerotic lesion volume in FXI-deficient animals [69] . Even though the direct link between FXI and inflammation is still unknown, decreased levels of TNF-a and IL-6 have been observed in septic mice with inhibition of FXI activation [70] , thereby providing a potential link to reduced atherosclerosis in the absence of FXI. FXII deficiency, attenuated atherosclerosis in mice on an atherogenic background and reduced levels of inflammatory markers such as serum IL-1b and IL-12 suggest an antiinflammatory mechanism [71] . FVIII deficiency is also associated with sustained protection against atherosclerotic progression in ApoE À/À mice, but not in LDL-R À/À mice, suggesting an underlying lipid-dependent mechanism in LDL-R À/À mice [72] . In contrast to FVIII, FXII and FXI deficiency, FIX deficiency does not seem to protect against atherosclerosis in an experimental model [73] .
Anticoagulants and protection against atherosclerosis
Given the pivotal role of coagulation proteases in the development and progression of atherosclerosis, it seems straightforward to hypothesize that anticoagulant therapy might be beneficial for reduction of atherosclerosis. However, the picture is two-faced, as the outcome of coagulation inhibition on the extent of atherosclerosis seems to be dependent on the class of anticoagulant used. Although the vitamin K antagonists (VKAs) such as warfarin and coumarin derivatives decrease the incidence of cardiovascular events [74, 75] , it has been demonstrated that long-term administration of VKAs leads to an increase in vascular calcification [76] as a result of incomplete c-glutamyl carboxylation of matrix Gla protein [77, 78] . In contrast, direct inhibition of coagulation enzymes may have antiatherosclerotic effects. Regarding, first, FXa anticoagulation, several experimental animal studies have demonstrated reduced atherosclerosis following treatment with a direct FXa inhibitor. A study by Hara et al. demonstrated that the development of atherosclerosis in mice is reduced after administration of the FXa inhibitor rivaroxaban. The diminished progression of atherosclerosis was accomplished by stabilization of already developed atherosclerotic plaques through inhibition of lipid deposition, but also by reducing collagen loss and the accumulation of macrophages [79] . In a different study, reduction of atherosclerotic volume upon treatment with rivaroxaban was less evident, although a small but significant increase in the minimum thickness of the fibrous cap was noticed, suggesting a more stable plaque phenotype [61] . The inhibition of FXa was accompanied by reduced expression of the proinflammatory markers IL-6, TNF-a, and MCP-1, which are known to promote atherosclerotic progression. The second group of direct oral anticoagulants (DOACs) consists of direct thrombin inhibitors (DTIs), which exert their effect on thrombin itself rather than on its amplification pathway. One of the first experimental studies demonstrating reduced atherosclerosis upon treatment with a thrombin inhibitor was performed with melagatran [80] . Atherosclerosis in ApoE -/-mice receiving a diet containing melagatran was reduced in terms of lesion area and thickness, as well as by increased plaque stability through reduced activation of proinflammatory transcription factors and reduced synthesis of MMP-9. These observations were confirmed by use of dabigatran etexilate as a DTI. After demonstrating the vascular protective effects of melagatran in mice, Kadoglou et al. found that, after administration of dabigatran etexilate, plaques became smaller and more stable, owing to increases in the amounts of collagen and elastin. The fibrous cap also became thicker, with an increase in mechanical strength via upregulation of smooth muscle cells [81] . [67] . It has been suggested that DTIs have their greatest effect on early atherosclerotic lesions, owing to a more stimulated coagulation system in the early stages of atherosclerosis. In these early stages, thrombin may be a particularly important driver of macrophage recruitment by inducing the transcription of proinflammatory genes. High levels of macrophages are present in atherosclerotic lesions, induced by thrombin itself. Administration of a DTI might therefore be most profitable in the early stages of atherosclerosis [83] .
Atherothrombotic protection in clinical studies
DOACs have been clinically introduced mainly on the basis of studies on the prevention and treatment of venous thromboembolism and prevention of stroke in subjects with atrial fibrillation [84] . Over the past few years, clinical research has been expanded to involve the prevention of atherothrombosis in both acute and stable manifestations of atherosclerotic vascular disease (Fig. 3) . Patients with acute coronary syndrome treated with rivaroxaban in conjunction with platelet inhibitors have a reduced risk for a secondary event or cardiovascular death as compared with patients treated solely with platelet inhibitors [85, 86] . The price of combining rivaroxaban and platelet inhibitors was an increase in major bleeding, without an increased risk of fatal intracerebral bleeding. The APPRAISE-2 trial investigated the combination of apixaban with aspirin or aspirin/clopidogrel in patients with acute coronary syndrome, and showed no clear benefit in terms of reductions in the rates of recurrent arterial events or death, and an increased risk of major, including fatal, bleeding [87] . From these studies, the concept of potential benefit of a combination of a relatively low dose of a DOAC (rivaroxaban) with antiplatelet therapy emerged; however, practical implementation appears to be limited by the associated bleeding risks.
There are no studies on the management of DOACs in patients with acute ischemic stroke; here, the use of single or short-lasting double antiplatelet therapy remains standard [88] . Obviously, large studies have addressed the prevention of acute ischemic stroke (and other vascular events, including mortality) in patients with atrial fibrillation [89, 90] . None of the studies addressed the effects on atherosclerosis, except for the RE-LY study, which showed an increased risk of myocardial infarction in those treated with dabigatran as compared with those treated with warfarin [91] [92] [93] . The origin of this effect remains unclear, and there are no indications that effects on plaque stability, as suggested by preclinical studies with dabigatran (see above), are involved, but this has also not been addressed specifically.
In the management of patients with stable (i.e. nonacute) atherosclerotic vascular disease, the use of platelet inhibitors has been the cornerstone of antithrombotic management. In general, this involves the use of one antiplatelet agent, i.e. aspirin or clopidogrel, and rarely dual antiplatelet therapy (beyond the guideline-supported interval use after a coronary intervention), because of the associated increased risk of bleeding complications as compared with single-agent therapy [94] .
The recent COMPASS trial triggered interest in the use of combined anticoagulant and antiplatelet therapy in patients with relatively high-risk atherosclerotic disease. In particular, in patients with peripheral artery disease, combined rivaroxaban (2.5 mg) and aspirin were more effective than either agent alone in reducing the rates of major adverse cardiovascular events and major adverse limb events, although at the cost of more bleeding events [95] . The potential advantage of this combined antithrombotic treatment may be profound, at least from a conceptual point of view. On the one hand, the use of platelet inhibition and anticoagulants makes sense, as atherothrombosis is dependent not only on platelets, but also on fibrin formation. On the other hand, preclinical data from mouse studies suggest that (long-term) administration of anticoagulants (at least DOACs) may also have beneficial effects on atherosclerosis. The challenge will be to address the underlying mechanisms of such combined therapy that may extend beyond simply lowering the thrombosis risk (also, for these low doses of rivaroxaban, supported by marked attenuation of thrombin generation levels [96] ). This requires further preclinical studies, also with other DOACs alone and in combination with antiplatelet therapy. In addition, we argue for more clinical studies investigating the potential vascular effects of (long-term) oral anticoagulant therapy, to carefully address the existence and magnitude of such effects in patients with defined vascular disease; such studies will require sensitive imaging tools and biomarkers, rather than clinical endpoints.
Conclusion
As cardiovascular disease is the most important cause of death worldwide, optimization of secondary prevention remains a huge healthcare issue. Although secondary cardiovascular prevention is based on different treatment strategies, anticoagulant therapy is a key player. Preclinical evidence suggests that DOACs, in particular, may have vascular effects beyond the prevention of thrombosis. The clinical efficacy of relatively low doses of a DOAC in combination with antiplatelet therapy suggests, although at the cost of bleeding, that efficacy regarding cardiovascular events can still be optimized.
More clinical studies on DOACs in secondary cardiovascular prevention are necessary to investigate efficacy and safety, especially in subgroups such as patients with peripheral artery disease.
